Platelet-Rich Plasma for Intra-articular Injections: Preclinical and Clinical Evidence

Angelo Boffa; Giuseppe Filardo

doi:10.1007/978-1-0716-2839-3_28

Platelet-Rich Plasma for Intra-articular Injections: Preclinical and Clinical Evidence

Methods Mol Biol. 2023:2598:381-390. doi: 10.1007/978-1-0716-2839-3_28.

Authors

Angelo Boffa¹, Giuseppe Filardo^{2

3

4}

Affiliations

¹ Applied and Translational Research Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. angelo.boffa@ior.it.
² Applied and Translational Research Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
³ Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland.
⁴ Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

PMID: 36355307
DOI: 10.1007/978-1-0716-2839-3_28

Abstract

The use of platelet-rich plasma (PRP) has been supported by encouraging data from in vitro and preclinical in vivo studies, both in terms of safety and efficacy. This led to the wide use of PRP injections in the clinical practice, with promising results especially as a minimally invasive treatment for cartilage degeneration and osteoarthritis (OA). While many controversies remain on the best PRP formulation, the overall available clinical studies support the benefits of PRP, with functional improvement and reduction of pain-related symptoms up to 12 months, especially in young patients and early OA stages.

Keywords: Cartilage; Injection; Intra-articular; Osteoarthritis; PRP; Platelet-rich plasma.

MeSH terms

Humans
Hyaluronic Acid
Injections, Intra-Articular
Osteoarthritis* / drug therapy
Osteoarthritis, Knee*
Pain / drug therapy
Platelet-Rich Plasma*
Treatment Outcome

Substances

Hyaluronic Acid